Signalling via vascular endothelial growth factor receptor‐3 is sufficient for lymphangiogenesis in transgenic mice

By Tanja Veikkola, L. Jussila, Taija Makinen, Terhi Karpanen, M. Jeltsch, T. Petrova, H. Kubo, Gavin Thurston, D. McDonald, M. Achen and 2 more. EMBO Journal, 2001

691 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Physiology

View Paper: https://www.semanticscholar.org/paper/b948c076d038dc7d0e951057909b39634b98639e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. K. Alitalo
2. Peter Carmeliet
3. Rakesh K. Jain
4. N. Ferrara
5. M. Shibuya
6. J. Joyce
7. J. Folkman
8. C. Iadecola

In Oncology

1. Peter Carmeliet
2. K. Alitalo
3. M. Shibuya
4. Rakesh K. Jain
5. N. Ferrara

In Physiology

1. K. Alitalo

Citations in the corpus

• Abnormal lymphatic vessel development in neuropilin 2 mutant mice. (2002, background): “A role for VEGFR3 as the signaling receptor mediating VEGFC or VEGFD actions was suggested by overexpression of a VEGFC form that does not bind VEGFR2 (VEGF-C156S) in the skin of mice, which also stimulates lymphangiogenesis (Veikkola et al., 2001).”
• Molecular mechanisms of lymphangiogenesis in health and disease. (2002, background): “VEGFR-2, induced a similar phenotype (Veikkola et al., 2001).”